Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Share-based Compensation for 7 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 46.24% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.2 million, a 30.28% decrease, with the full-year FY2025 number at $26.2 million, down 30.28% from a year prior.
  • Share-based Compensation was $4.5 million for Q4 2025 at Pliant Therapeutics, down from $6.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.0 million in Q2 2023 to a low of $2.3 million in Q2 2021.
  • A 5-year average of $7.1 million and a median of $7.4 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 506.59% in 2021, then tumbled 46.24% in 2025.
  • Pliant Therapeutics' Share-based Compensation stood at $2.8 million in 2021, then soared by 292.16% to $10.9 million in 2022, then dropped by 15.69% to $9.2 million in 2023, then dropped by 8.03% to $8.4 million in 2024, then crashed by 46.24% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Share-based Compensation are $4.5 million (Q4 2025), $6.4 million (Q3 2025), and $6.4 million (Q2 2025).